Sunshine Guojian Reports 2025 Net Profit of 2.94 Billion Yuan, Surging 317%

Stock News02-24

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) announced its 2025 financial results, revealing a significant increase in performance. The company's operating revenue for the year reached 4.199 billion yuan, representing a substantial increase of 251.81% compared to the previous year. Net profit attributable to the parent company's owners amounted to 2.939 billion yuan, marking a remarkable surge of 317.09%.

Key financial metrics, including total operating revenue, operating profit, total profit, net profit attributable to owners of the parent company, net profit attributable to owners of the parent company after deducting non-recurring gains and losses, basic earnings per share, total assets, and owner's equity attributable to the parent company, all showed significant year-on-year growth.

This substantial growth was primarily driven by a major collaboration agreement with Pfizer Inc. During the reporting period, the company received an initial authorization payment from Pfizer for the 707 project, leading to the recognition of approximately 2.89 billion yuan in revenue.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117737106?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 16:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117737106","market":"us","top_or_hot":-1,"title":"Sunshine Guojian Reports 2025 Net Profit of 2.94 Billion Yuan, Surging 317%","media":"Stock News","content":"<p>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) announced its 2025 financial results, revealing a significant increase in performance. The company's operating revenue for the year reached 4.199 billion yuan, representing a substantial increase of 251.81% compared to the previous year. Net profit attributable to the parent company's owners amounted to 2.939 billion yuan, marking a remarkable surge of 317.09%.</p>\n<p>Key financial metrics, including total operating revenue, operating profit, total profit, net profit attributable to owners of the parent company, net profit attributable to owners of the parent company after deducting non-recurring gains and losses, basic earnings per share, total assets, and owner's equity attributable to the parent company, all showed significant year-on-year growth.</p>\n<p>This substantial growth was primarily driven by a major collaboration agreement with Pfizer Inc. During the reporting period, the company received an initial authorization payment from Pfizer for the 707 project, leading to the recognition of approximately 2.89 billion yuan in revenue.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sunshine Guojian Reports 2025 Net Profit of 2.94 Billion Yuan, Surging 317%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSunshine Guojian Reports 2025 Net Profit of 2.94 Billion Yuan, Surging 317%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-24 16:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) announced its 2025 financial results, revealing a significant increase in performance. The company's operating revenue for the year reached 4.199 billion yuan, representing a substantial increase of 251.81% compared to the previous year. Net profit attributable to the parent company's owners amounted to 2.939 billion yuan, marking a remarkable surge of 317.09%.</p>\n<p>Key financial metrics, including total operating revenue, operating profit, total profit, net profit attributable to owners of the parent company, net profit attributable to owners of the parent company after deducting non-recurring gains and losses, basic earnings per share, total assets, and owner's equity attributable to the parent company, all showed significant year-on-year growth.</p>\n<p>This substantial growth was primarily driven by a major collaboration agreement with Pfizer Inc. During the reporting period, the company received an initial authorization payment from Pfizer for the 707 project, leading to the recognition of approximately 2.89 billion yuan in revenue.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688336","symbol_name":"三生国健","start_time":0,"source_url":"","article_id":"1117737106","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117737106","pubTimestamp":1771921458,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) announced its 2025 financial results, revealing a significant increase in performance. The company's operating revenue for the year...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688336":"三生国健","BK0239":"医药制造"},"translate_title":"三生国健报告2025年净利29.4亿元暴增317%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688336":1},"content_text":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (688336.SH) announced its 2025 financial results, revealing a significant increase in performance. The company's operating revenue for the year reached 4.199 billion yuan, representing a substantial increase of 251.81% compared to the previous year. Net profit attributable to the parent company's owners amounted to 2.939 billion yuan, marking a remarkable surge of 317.09%.\nKey financial metrics, including total operating revenue, operating profit, total profit, net profit attributable to owners of the parent company, net profit attributable to owners of the parent company after deducting non-recurring gains and losses, basic earnings per share, total assets, and owner's equity attributable to the parent company, all showed significant year-on-year growth.\nThis substantial growth was primarily driven by a major collaboration agreement with Pfizer Inc. During the reporting period, the company received an initial authorization payment from Pfizer for the 707 project, leading to the recognition of approximately 2.89 billion yuan in revenue.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117737106","isCrawlerRequest":true}